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Summary
We develop a new Bayesian approach of sample size determination (SSD) for the design of non-
inferiority clinical trials. We extend the fitting and sampling priors of Wang and Gelfand (2002) to
Bayesian SSD with a focus on controlling the type I error and power. Historical data are
incorporated via a hierarchical modeling approach as well as the power prior approach of Ibrahim
and Chen (2000). Various properties of the proposed Bayesian SSD methodology are examined
and a simulation-based computational algorithm is developed. The proposed methodology is
applied to the design of a non-inferiority medical device clinical trial with historical data from
previous trials.
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1. Introduction
Recently, the FDA released “Guidance for the Use of Bayesian Statistics in Medical Device
Clinical Trials” (February 5, 2010,
www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/
ucm071072.htm). This document provides guidance on statistical aspects of the design and
analysis of Bayesian clinical trials for medical devices. It lays out detailed guidance on the
determination of sample size in a Bayesian clinical trial. This document also provides
guidance on the evaluation of the operating characteristics of a Bayesian clinical trial design.
Specifically, the evaluation of a Bayesian clinical trial design should include type I error
(probability of erroneously approving an ineffective or unsafe device), type II error
(probability of erroneously disapproving a safe and effective device), and power (the
converse of type II error: the probability of appropriately approving a safe and effective
device).
Sample size determination (SSD) is a crucial aspect of clinical trial design. In this paper, we
are particularly interested in the design and analysis of non-inferiority trials. There is a vast
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for example, D’Agostino Sr. et al. (2003), Hung et al. (2003), Rothmann et al. (2003), Hung
et al. (2005), Kieser and Friede (2007), and Fleming (2008). The literature on Bayesian SSD
has been growing recently due to recent advances in Bayesian computation and Markov
chain Monte Carlo sampling. Joseph et al. (1995), Lindley (1997), Rubin and Stern (1998),
Katsis and Toman (1999), and Inoue et al. (2005) are the Bayesian SSD articles cited in the
FDA 2010 Guidance. An early review of Bayesian SSD is given in Adcock (1997). The
most recent work includes Rahme and Joseph (1998), Simon (1999), Wang and Gelfand
(2002), De Santis (2007), and M’Lan et al. (2006, 2008). The existing literature on Bayesian
SSD primarily focuses on simple normal, one or two sample binomial problems, standard
normal linear regression, and generalized linear models. Although the literature on Bayesian
SSD discusses a variety of performance criteria, the widely used ones include the Bayes
factor (Weiss, 1997), the average posterior variance criterion (APVC) (see, for example,
Wang and Gelfand, 2002), the average coverage criterion (ACC), the average length
criterion (ALC), the worst outcome criterion (WOC) (e.g., Joseph et al., 1995 and Joseph
and Bélisle, 1997), and the approach based on the range of equivalence (see, for instance,
Spiegelhalter et al., 2004) for superiority/non-inferiority trials. Other criteria have also been
considered in the literature, including Lindley (1997), Pham-Gia (1997), Lam and Lam
(1997), and M’Lan et al. (2006, 2008). However, most of the aforementioned Bayesian
articles do not directly address design and analysis of non-inferiority trials except for
Spiegelhalter et al. (2004).
The rest of the paper is organized as follows. In Section 2, we present the design of a non-
inferiority trial with two treatment arms for evaluating the performance of a new generation
of medical devices in order to motivate the methodology developed in this paper. The
availability of historical data from first generation medical devices is also discussed in
detail. In Section 3, we propose a general framework of Bayesian SSD for designing a non-
inferiority trial. Section 4 provides a detailed development of the incorporation of historical
data via the hierarchical modeling approach as well as the power prior formulation. The
posterior distribution is discussed and a simulation-based computational algorithm is
developed in Section 5. In Section 6, we apply the proposed methodology to sample size
determination of the non-inferiority medical device trial discussed in Section 2. The
proposed Bayesian SSD method is compared to frequentist SSD methods. We show that
Bayesian SSD yields a substantial reduction in the sample size compared to a frequentist
design. We conclude the paper with some discussion and extension of the proposed
Bayesian SSD method in Section 7.
2. Design of A Non-Inferiority Trial with Two Treatment Arms for Medical
Devices
We consider designing a clinical trial to evaluate the performance of a new generation of
drug-eluting stent (DES) (“test device”) with a non-inferiority comparison to the first
generation of DES (“control device”). Thus, the trial has two arms: test device and control
device. The primary endpoint is the 12-month Target Lesion Failure (TLF) (binary)
composite endpoint, which is an ischemia-driven revascularization of the target lesion
(TLR), myocardial infarction (MI) (Q-wave and non-Q-wave) related to the target vessel, or
(cardiac) death related to the target vessel. The secondary endpoint is the 9-month in-
segment percent diameter stenosis (%DS) (continuous), which is the percentage of
narrowing in the coronary artery caused by the plaque. Let  and
 be the data corresponding to the test device and the control device,
respectively, collected from this trial. Let n = nt + nc denote the total sample size. Also, we
write . We assume that the ratio of two sample sizes, , is fixed.
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Thus,  and . We choose r to be small, for example, r = 1/4, so that nt > nc. The
goal of the trial is to show that the test device is non-inferior to the control device.
We assume that  and  are two independent random samples. For the primary
endpoint, we assume that yti (yci) follows a Bernoulli distribution Ber(pt) (Ber(pc)). Let
 and . For the secondary endpoint, we assume that yti ~ N(μt, σ2)
and yci ~ N(μc, σ2) independently. Let θ = (μt, μc) for the primary endpoint and θ = (μt, μc,
σ2) for the secondary endpoint. Then, the joint distribution of y(n) for the primary endpoint is
given by
(2.1)
and the joint distribution of y(n) for the secondary endpoint is given by
(2.2)
The design parameter is the difference between μt and μc, namely, μt − μc, and the
hypotheses for non-inferiority testing are
(2.3)
where δ is a prespecified non-inferiority margin. The trial is successful if H1 is accepted.
Historical data are available from two previous trials on the first generation of DES. The
first trial conducted in 2002 evaluated the safety and effectiveness of the slow release
paclitaxel-eluting stent for treatment of de novo coronary artery lesions. The second trial
conducted in 2004 expanded on the first trial, studied more complex de novo lesions, and
involved multiple overlapping stents and smaller and larger diameter stents. Our historical
data based on lesion size matched criteria are subsets of the data published in Stone et al.
(2004, 2005). A summary of the historical data is given in Table 1. In Table 1, SD stands for
standard deviation.
In the next two sections, we will develop the general methodology for Bayesian SSD and
elicit priors via historical data.
3. The General Methodology
We first develop a new but general method to determine Bayesian sample size for a non-
inferiority trial. Denote the data associated with a sample size of n by y(n) and let θ be the
vector of all the model parameters. Then, the joint distribution of y(n) and θ is written as
f(y(n)|θ)π(θ), where π(θ) denotes the prior distribution. Let h(θ) be a scalar function that
measures the “true” size of the treatment effect. Then, let δ denote the non-inferiority
margin. Similar to Hung et al. (2003), we assume that the hypotheses for non-inferiority
testing can be formulated as follows:
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Consequently, we let Θ0 and Θ1 denote the parameter spaces corresponding to H0 and H1.
For the hypotheses given in (2.3), h(θ) = μt − μc; Θ0 = {θ = (μt, μc): μt − μc ≥ δ} and Θ1 =
{θ: μt − μc < δ} for the primary endpoint; and Θ0 = {θ = (μt, μc, σ2): μt − μc ≥ δ, σ2 > 0} and
Θ1 = {θ: μt − μc < δ, σ2 > 0} for the secondary endpoint.
Following Wang and Gelfand (2002), let π(s)(θ) denote the sampling prior and also let π(f)(θ)
denote the fitting prior. The sampling prior, which captures a certain specified portion of the
parameter space in achieving a certain level of performance in SSD, is used to generate the
data while the fitting prior is used to fit the model once the data is obtained. We note that
π(f)(θ) may be improper as long as the resulting posterior, π(f)(θ|y(n)) ∝ f(y(n)|θ)π(f)(θ), is
proper. Further we let f(s)(y(n)) denote the marginal distribution that is induced from the
sampling prior. Now, we introduce the key quantity
(3.2)
where the indicator function 1{A} is 1 if A is true and 0 otherwise, γ > 0 is a prespecified
quantity, the probability is computed with respect to the posterior distribution given the data
y(n) and the fitting prior π(f)(θ), and the expectation is taken with respect to the marginal
distribution of y(n) under the sampling prior π(s)(θ).
Now, we propose a new Bayesian SSD algorithm as follows. Let Θ ̄0 and Θ ̄1 denote the
closures of Θ0 and Θ1. Let  denote a “sampling prior” with support ΘB = Θ ̄0 ∩ Θ ̄1.
Also let  denote a “sampling prior” with support . For given α0 > 0 and α1 > 0,
we compute
(3.3)
where  and  given in (3.2) corresponding to  and  are the Bayesian
type I error and power, respectively. Then, the Bayesian sample size is given by nB =
max{nα0, nα1}. According to the FDA 2010 Guidance, we choose γ ≥ 0.95. Common
choices of α0 and α1 include α0 = 0.05 and α1 = 0.20 so that the Bayesian sample size nB
guarantees that the type I error rate is less than or equal to 0.05 and the power is at least
0.80. In addition, for a given sample size nB, the operating characteristic curve can be
constructed by varying  inside of Θ1. If h(θ) is a monotonic function of the distance
between  and ΘB, then the further  is away from ΘB, the higher the power will be.
A simple illustration: i.i.d. normal case
Suppose y1, y2, …, yn are i.i.d. N (θ, τ−1), where τ is a known precision parameter. Suppose
the hypotheses for non-inferiority testing are formulated as follows: H0: θ ≥ δ versus H1: θ <
δ. We specify an improper uniform fitting prior for θ, i.e., π(f)(θ) ∝ 1. In addition, we specify
two point mass sampling priors for θ such that  if θ = δ and  if θ = 0. After
some algebra, we can show that (i) a necessary condition for achieving a type I error rate of
α0 is 1 − γ ≤ α0 and (ii) if 1 − γ ≤ α0, the Bayesian sample size is the smallest integer nB
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satisfying , where Φ denotes the N(0, 1) cumulative
distribution function. It is interesting to note that for this simple case,  always holds
for all n when 1 − γ ≤ α0. We also note that the Bayesian sample size nB is identical to the
classical sample size formulation for a one-sided alternative hypothesis when α0 = 1 − γ.
4. The Incorporation of Historical Data in Bayesian SSD
Historical data are often available only for the control medical device. Now suppose that
there are K historical datasets for the control device, denoted by yc0k = (yc0k1, …, yc0kn0k)′
for k = 1, …, K. Let  denote all K historical datasets. We develop two
approaches, namely, the hierarchical prior and the power prior, to incorporate the historical
data yc0.
4.1 Hierarchical Priors
Under the hierarchical Bernoulli/normal model, we assume that yc0k follows the same model
given in either (2.1) or (2.2). Let θ0 = (μc01, …, μc0K)′(or θ0 = (μc01, …, μc0K, σ2)′) for the
primary (or secondary) endpoint. Then, the joint distribution of yc0 is given by
 for the primary endpoint and
 for the secondary endpoint. We further
assume μc ~ N(μc0, τ2), where &tau;2 > 0, and independently μc0k ~ N (μc0, τ2) for k = 1, …,
K.
Let θ* = (μt, μc, θ0, μc0, τ2)′. Then, the hierarchical prior for θ* is given by
(4.1)
where φ(·|μc0, τ2) denotes the probability density function (pdf) of a N(μc0, τ2) distribution.
In (4.1), π0(μt, σ2, μc0, τ2) is the initial prior, which is specified as
, where ξ0 > 0 and η0 > 0 are two prespecified
hyperparameters. The joint prior in (4.1) is improper since an improper uniform prior is
assumed for μt and the historical data are borrowed for μc and σ2 via the hierarchical model.
Finally, the fitting prior is obtained after integrating out μc01, …, μc0K, μc0, and τ2 from
(4.1). Specifically, we have
(4.2)
To specify the sampling prior π(s)(θ), we assume μt, μc, and σ2 are independent and then
specify point mass priors for μt and μc and use the historical data to specify the sampling
prior for σ2. Specifically, we take
(4.3)
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, and  and  are prespecified hyperparameters, which may be different from (ξ0,
η0). As discussed in Section 3, the sampling prior must be proper. We can show that under
very mild conditions, the sampling prior π(s)(σ2) is proper.
We note that under the normal model, the hierarchical prior (4.1) for θ* reduces to
(4.4)
where  and  for k = 1, …, K.
Thus, the fitting prior and the sampling prior depend only on the sufficient statistics {(ȳ0k,
), k = 1), …, K} from the historical data.
4.2 Power Priors
We extend the power priors of Ibrahim and Chen (2000) to build the prior distribution for μc
or (μc, σ2) when multiple historical datasets are available. For the primary endpoint, we
consider the following normalized power prior for μc given multiple historical data yc0,
(4.5)
where a0 = (a01, …, a0K)′, 0 ≤ a0k ≤ 1 for k = 1, 2, …, K, π0(μc) is an initial prior, and
. When π0(μc) ∝ 1, (4.5) reduces to
where B(., .) denotes the complete beta function, , and ȳc0k is defined in
(4.4). For the secondary endpoint, the normalized power prior for μc and σ2 is given by
(4.6)
where π0(μc, σ2) is an initial prior and C(a0) is the normalizing constant, which is similar to
the one in (4.5). Let  and
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, where ȳc0k and  are defined
in (4.4). When π0(μc, σ2), ∝ 1/σ2, (4.6) reduces to
. To
complete the specification of the power prior, we assume that the a0k’s are independent and
distributed as a0k ~ beta(b01, b02), where b01 > 0 and b02 > 0 are prespecified
hyperparameters. We mention that the normalized power prior is also considered by Duan et
al. (2006),Neuenschwander et al. (2009), and Hobbs et al. (2009).
Using (4.5) or (4.6), the fitting prior of θ is of the form
(4.7)
where π(θ̃|(yc0, a0) = π(μc|yc0, a0) defined in (4.5) and θ̃ = μc for the primary end-point, and
π(θ̃|yc0, a0) = π(μc, σ2|yc0, a0) defined in (4.6) and θ̃ = (μc, σ2) for the secondary endpoint.
Similar to the hierarchical prior, the sampling prior π(s)(θ) under the normalized power prior
is specified as follows: π(s)(θ) = π(s)(μt)π(s)(μc) or π(s)(θ) = π(s)(μt) π(s)(μc)π(s)(σ2), where π(s)
(μt) and π(s)(μc) are two prespecified proper priors,
(4.8)
a0s is prespecified and  may be an improper initial prior such as .
In (4.5) or (4.6), the parameter a0k controls the influence of the kth historical dataset on π(θ̃|
yc0, a0). The parameter a0k can be interpreted as a relative precision parameter for the kth
historical dataset. One of the main roles of a0 is that it controls the heaviness of the tails of
the prior for μc (or (μc, σ2)). As all of the a0k’s become smaller, the tails of (4.5) or (4.6)
become heavier. When a0k = 1 for all k with probability 1, (4.7) corresponds to the update of
π0(θ) using Bayes theorem based on the historical data. When a0 = 0 with probability 1, then
the power prior does not depend on the historical data. That is, a0 = 0 is equivalent to a prior
specification with no incorporation of historical data. Thus, the a0k’s control the influence of
the multiple historical datasets on the current study. Such control is important in cases where
there is heterogeneity among the historical studies, or heterogeneity between the historical
and current studies, or when the sample sizes of the historical and current studies are quite
different.
We note that the use of historical data via the power priors for Bayesian sample size
determination is also considered by De Santis (2007). We also note that a0 may be
considered to be fixed instead of random. For ease of exposition, we consider the primary
endpoint. When a0 is fixed, the fitting prior of θ = (μt, μc)′ is of the form π(f)(θ|yc0) ∝ π(μc|
yc0, a0) π0(μt), where π(μc|yc0, a0) is given by (4.5), π0(μt) is an initial prior for μt, and a0 is
fixed. When a0 is fixed, we know exactly how much historical data are incorporated in the
new trial, and in addition, there is a theoretical connection between the power prior
formulation and the hierarchical prior specification as established in Chen and Ibrahim
(2006). De Santis (2006) also provides some useful comments on the fixed-a0 case as well
as on power priors for the exponential family. On the other hand, when a0 is random, the
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amount of incorporation of historical data is determined by the data and hence not
prespecified by the data analyst.
5. Posteriors and Computations
For ease of exposition, we only consider the primary endpoint. Instead of directly sampling
from π(f)(θ|y(n), yc0) ∝ f(y(n)|θ)π(f)(θ|yc0), where f(y(n)|θ) is given by (2.1) and π(f)(θ|yc0) is
defined in (4.2) or (4.7), we consider the augmented fitting posterior distribution parameters
θ*, where θ* = (μt, μc, μc01, …, μc0K, μc0, τ2)′ for the hierarchical prior and θ* = (μt, μc, a0)
for the normalized power prior. Then, the augmented fitting posterior distribution of θ* is
given by π(f)(θ*|y(n), yc0) ∝ f(y(n)|θ) π(θ*|yc0), where π(θ*|yc0) is defined in (4.1) under the
hierarchical prior, and  with π(μc|
yc0, a0) defined in (4.5) under the normalized power prior. Although the posterior
distribution π(f)(θ*|y(n), yc0) is analytically intractable, sampling from this distribution via the
Gibbs sampler is quite straightforward, because the conditional posterior distributions of the
components of θ* (except for a0) are either known distributions or log-concave. For a0, we
use the localized Metropolis algorithm discussed in Chen et al. (2000) to sample from its
conditional posterior distribution.
Let {θ*(m), m = 1, 2, …, M} denote a Gibbs sample from the augmented fitting posterior
distribution π(f)(θ*|y(n), yc0). As θ is a subvector of θ*, let θ(m) denote the corresponding
components of θ*(m) from the mth Gibbs iteration. Then, it is easy to show that {θ(m), m = 1,
2, …, M} is a Gibbs sample from the fitting posterior distribution π(f)(θ|y(n), yc0). Using this
Gibbs sample, a Monte Carlo estimate of P(h(θ) < δ|y(n), π(f)) is given by
(5.1)
To compute  in (3.2), we propose the following computational algorithm: Step 0: Specify
nt, nc, δ, γ, and N; Step 1: Generate θ ~ π(s)(θ); Step 2: Generate y(n) ~ f(y(n)|θ); Step 3: Run
the Gibbs sampler to generate a Gibbs sample {θ(m), m = 1, 2, …, M} of size M from the
fitting posterior distribution π(f)(θ|y(n), yc0); Step 4: Compute P̂f via (5.1); Step 5: Check
whether P̂f ≥ γ; Step 6: Repeat Steps 1–5 N times; and Step 7: Compute the proportion of
{P̂f ~ ≥ γ} in these N runs, which gives an estimate of .
6. Applications to Medical Device Trials
We apply the proposed methodology in designing the non-inferiority clinical trial for
medical devices discussed in Section 2. We use the historical datasets given in Table 1 to
construct our priors in Bayesian SSD. We set γ = 0.95, which implies a target type I error of
0.05. We notice that the same γ value was also used in Allocco et al. (2010). In all of the
computations below, N = 10, 000 and M = 20, 000 were used.
Bayesian SSD for TLF
For the primary endpoint, the margin was set to be . We took (ξ0,
η0) = (0.01, 0.01) or (ξ0, η0) = (0.001, 0.001) for the initial prior of γ in the fitting prior (4.2),
π0(μc) ∝ 1 and b01 = b02 = 1 for the initial priors of μc and a0k in (4.7). We computed the
powers at μt = μc and the type I error at . In other words, we convert μj
back to pj in the Bernoulli case. In the sampling prior (4.3), we assumed a point mass prior
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at μc = logit(9.2%) for π(s)(μc), where 9.2% was the pooled proportion for the two historical
control datasets, and a point mass prior at μt = μc or  for π(s)(μ t). We
first computed the powers and the type I errors for various sample sizes based on the
proposed Bayesian SSD without the incorporation of historical data. Table 2 shows the
results. Table 2 also presents the powers of the two frequentist methods, namely, the z-test
with unpooled variances and the score test (Farrington and Manning, 1990) for non-
inferiority trials. For both frequentist methods, the target type I error was 0.05. In all
calculations, the margin δ = 0.041, pc = 9.2%, and a 3:1 sample size ratio were used. PASS
2008 (Hintze, 2008) was used for computing the powers for the two frequentist SSD
methods. We see from Table 2 that the proposed Bayesian SSD without incorporation of
historical data gives very similar powers compared to the score test for the frequentist SSD,
while the type I errors of the Bayesian SSD are controlled at or below 5%. Both the score
test and Bayesian SSD yield slightly higher powers than the z-test. In order to achieve 80%
power, the z-test requires a total sample size of 1636 with nt = 1227 and nc = 409.
Table 2 also shows the powers and the type I errors of the Bayesian SSD procedure with
hierarchical priors and power priors with fixed and random a0. The hierarchical prior with
(ξ0, η0) = (0.001, 0.001) leads to higher powers than the one with (ξ0, η0) = (0.01, 0.01). In
addition, the powers based on the power prior with a0 random are comparable to those based
on the hierarchical prior with (ξ0, η0) = (0.001, 0.001) and the power prior with a0 fixed at
a0 = (0.3, 0.3). These results imply that the power prior with random a0 and the hierarchical
prior with (ξ0, η0) = (0.001, 0.001) borrow approximately 30% of the historical data. With
incorporation of the historical data, a sample size of (nt, nc) = (810, 270) achieves 80%
power. However, based on the frequentist SSD or the Bayesian SSD without incorporation
of historical data, a sample size of 1480 with nt = 1110 and nc = 370 is required to achieve
80% power. Thus, the Bayesian SSD with incorporation of historical data leads to a
substantial reduction in the sample size.
Bayesian SSD for %DS
For the secondary endpoint, the margin was set to be δ = 0.20. We compute the power at μt =
μc and the type I error at μt = μc + δ. In the sampling prior (4.3), we assume a point mass
prior at μc = 3.15 for π(s) (μc) and a point mass prior μt = μc or μt = μc + δ for π(s) (μt). PASS
2008 (Hintze, 2008) was used to compute the powers of the frequentist SSD based on the
pooled SD = 0.607. In the Bayesian SSD procedure which does not use any historical data,
we used the same pooled SD for σ in generating the data. For the hierarchical prior, we took
(ξ0, η0) = (0.01, 0.01) or (ξ0, η0) = (0.001, 0.001) for the initial prior of τ in the fitting prior
(4.2) and ξ0 = 0.01 and η0 = 0.01 for the initial prior of τ in the sampling prior (4.3). For the
power priors, we used (4.8) with a0s = (0.05, 0.05) for the sampling prior π(s)(σ2). Using the
same sampling prior, we also computed the powers and type I errors with a fixed a0 = (0.08,
0.08) in the fitting prior. The results are shown in Table 3.
Similar to TLF, the Bayesian SSD procedure with no incorporation of historical data yields
similar powers, with the type I errors controlled at the 5% level, and the hierarchical prior
with (ξ0, η) = (0.001, 0.001) yields higher powers than the one with (ξ0, η = (0.01, 0.01).
From Table 3, we also see that the power prior with random a0 leads to slightly higher
powers than the hierarchical prior with (ξ0, η0) = (0.001, 0.001), and the powers based on the
power prior with random a0 are comparable to the power prior with a fixed a0 = (0.08, 0.08).
These results imply that the hierarchical prior borrows less than 8% of historical data, while
the power prior with random a0 borrows about 8% of the historical data. Similar to TLF, the
Bayesian SSD with incorporation of historical data again leads to a substantial reduction in
the sample size compared to the frequentist design.
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In this paper, we have developed a general methodology of Bayesian SSD, which is
particularly suitable for designing a non-inferiority clinical trial. We have discussed two
types of priors, namely, the hierarchical prior and the normalized power prior, to incorporate
historical data. We have shown that Bayesian SSD leads to a substantial reduction in the
sample size compared to frequentist SSD. One unique feature of the proposed Bayesian SSD
methodology is that we use the historical data only from the control device but not from the
test device. This feature is desirable, since for the test device, historical data are often not
available. Although we primarily focus on the Bernoulli and normal models in this paper,
our methodology is applicable to other models in the exponential family. In addition, the
proposed methodology can also be extended to generalized linear models (GLMs). The
computational algorithm given in Section 5 for these two extensions is basically the same.
However, there may be two potential complications. First, a closed-form expression of the
normalized power prior under GLMs may not be available. Therefore, an efficient Markov
chain Monte Carlo sampling algorithm needs to be developed to sample from the fitting
posterior distribution in Step 3 of the computational algorithm in Section 5. Second, the
determination of the non-inferiority margin may be more difficult for some GLMs than the
situation without covariates. For example, for binomial regression models, the non-
inferiority margin based on the difference in two proportions may not be easily converted to
the margin on the regression coefficient corresponding to the treatment effect. However, this
may not be an issue for other GLMs such as the normal linear regression model.
The proposed Bayesian SSD works best if the historical data from the control device are
compatible to the data from the current trial. However, the target type I error and power may
not be well maintained when the data from the historical and current trials are not
compatible. For non-inferiority trials, we have empirically observed that (i) the type I errors
are controlled but the powers are lower when the true proportions or means in the control
devices from the current trial are greater than those in the historical data; and (ii) the type I
errors tend to be larger, but the powers tend to be higher when the true proportions or the
true means for the control devices in the current trial are less than those in the historical
data. For illustrative purposes, we consider n = 1200 with nt = 900 and nc = 300 for the
primary endpoint TLF and n = 280 with nt = 210 and nc = 70 for the secondary endpoint
%DS. For %DS, if a point mass sampling prior at μc = 3.10 is assumed and γ = 0.95, the
powers and type I errors are 0.836 and 0.047 for the hierarchical priors with (ξ0, η0) = (0.01,
0.01) and 0.936 and 0.049 for the power prior with random a0; and if a point mass sampling
prior at μc = 3.20 is assumed, the powers and type I errors are 0.792 and 0.030 for the
hierarchical priors with (ξ0, η0) = (0.01, 0.01) and 0.815 and 0.004 for the power prior with
random a0. In all cases, the type I errors are still controlled at 0.05. However, for TLF, the
type I error is not controlled as shown in Table 4. Specifically, if a point mass sampling
prior at μc = logit(8.0%) is assumed, the type I errors are 0.068 for the hierarchical priors
with (ξ0, η0) = (0.01, 0.01) and 0.07 for the power prior with a0k ~ beta(1, 1) and γ = 0.95.
There are two approaches for resolving this type I error problem. One approach is to change
the initial prior beta(b01, b02) for a0k in (4.7) to down-weight the historical control data as
suggested by an anonymous Associate Editor. Another approach is to increase the value of γ,
which is recommended in the FDA 2010 Guidance. As shown in Table 4 for TLF, if a point
mass sampling prior at μc = logit(8.0%) is assumed, the type I error decreases in b02 when
b01 is fixed at 1. When (b01, b02) = (1, 10), which gives an initial prior weight of 10% to the
historical control data, the type I error is 0.053. Also, we see from Table 4 that for a fixed
initial prior beta(b01, b02), the type I error decreases in γ. In particular, when (b01, b02) = (1,
1) and γ = 0.97, the type I error is 0.041 if a point mass sampling prior at μc = logit(8.0%) is
assumed. A combination of these two approaches is also quite effective in controlling the
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type I error while maintaining good power as shown in Table 4. Further methodological
approaches for controlling the type I error are currently under investigation.
Finally, we briefly discuss how to determine whether the trial is successful after it is
completed. The computational algorithm developed in Section 5 can still be used for this
purpose. Specifically, the following algorithm can be used to determine the outcome of the
trial: Step 0: Use the same γ and the same fitting prior specified at the design stage; Step 1:
Obtain the data y(n) at the completion of the trial; Step 2: Run the Gibbs sampler to generate
a Gibbs sample {θ(m), m = 1, 2, …, M} of size M from the fitting posterior distribution π(f)(θ|
y(n), yc0); Step 3: Compute P̂f via (5.1); and Step 4: Declare a success of the trial if P̂f ≥ γ.
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Table 1
Historical Data
12-Month TLF log(9-month %DS)
% TLF (# of failure/n0k) mean ± SD (n0k)
Historical Trial 1 8.2% (44/535) 3.0891 ± 0.6315 (242)
Historical Trial 2 10.9% (33/304) 3.1849 ± 0.5811 (263)
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